Value
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 1.0 |
| P/S | 9.9 |
| EV/EBITDA | 6.7 |
| Fwd P/E | 9.9 |
| PEG | 10.0 |
| Analyst target | 5.0 |
- ▸Forward P/E: 5.7x
- ▸PEG: 0.05
- ▸Attractively valued
IART · Why this verdict
Why Integra LifeSciences Holdings C (IART) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Integra LifeSciences has beaten earnings four quarters running, trades at a forward P/E of 5.0x and sits 18.5% below its $14.11 analyst target, but momentum is weak after a 42% drawdown and 70% of revenue comes from one segment.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Integra beat EPS estimates in all 4 of the last 4 quarters, with an average surprise of about 14.8% and $0.59 actual against $0.56 estimated last quarter. Earnings | EPS should continue to meet or beat consensus over the next 4 quarters. | ↓Deteriorating |
| CounterThe latest surprise of 5.5% is the smallest of the streak, and an analyst downgrade warning is flagged, so the beat cushion may be narrowing. | ||
Integra trades at a forward P/E of 5.0x with a PEG of 0.05, flagged as attractively valued. Valuation breakdown | Forward P/E should rise toward 8x or higher as price recovers while earnings hold. | ↓Deteriorating |
| CounterA forward P/E of 5.0x after a 42% drawdown may signal that the market expects earnings estimates to fall. | ||
The $11.91 price sits 18.5% below the $14.11 analyst target against a 12.0% modeled downside, a reward-to-risk of 1.5. Targets | Price should move toward the $14.11 target as earnings continue to beat over 12 months. | ↓Deteriorating |
| CounterAnalyst upside of 36% before the haircut has not prevented a drawdown, and the downgrade warning suggests targets could be lowered. | ||
The CSS segment makes up 70.0% of the product mix, concentrating revenue in one business. Bear case | The segment should hold revenue without a material decline over the next 12 months. | ↓Deteriorating |
| CounterA setback in the CSS segment would hit most of the company's revenue because there is no diversification. | ||
Momentum is 2.4/10 with falling on-balance volume, short interest is 13% and the put/call ratio is 2.14. Momentum breakdown | Price should reclaim the 200-day moving average and short interest should fall below 10%. | ↑Improving |
| CounterDistribution volume with elevated short interest and put buying shows active bearish positioning. | ||
Integra beat EPS estimates in all 4 of the last 4 quarters, with an average surprise of about 14.8% and $0.59 actual against $0.56 estimated last quarter.
↓DeterioratingEarnings
- Expectation
- EPS should continue to meet or beat consensus over the next 4 quarters.
CounterThe latest surprise of 5.5% is the smallest of the streak, and an analyst downgrade warning is flagged, so the beat cushion may be narrowing.
Integra trades at a forward P/E of 5.0x with a PEG of 0.05, flagged as attractively valued.
↓DeterioratingValuation breakdown
- Expectation
- Forward P/E should rise toward 8x or higher as price recovers while earnings hold.
CounterA forward P/E of 5.0x after a 42% drawdown may signal that the market expects earnings estimates to fall.
The $11.91 price sits 18.5% below the $14.11 analyst target against a 12.0% modeled downside, a reward-to-risk of 1.5.
↓DeterioratingTargets
- Expectation
- Price should move toward the $14.11 target as earnings continue to beat over 12 months.
CounterAnalyst upside of 36% before the haircut has not prevented a drawdown, and the downgrade warning suggests targets could be lowered.
The CSS segment makes up 70.0% of the product mix, concentrating revenue in one business.
↓DeterioratingBear case
- Expectation
- The segment should hold revenue without a material decline over the next 12 months.
CounterA setback in the CSS segment would hit most of the company's revenue because there is no diversification.
Momentum is 2.4/10 with falling on-balance volume, short interest is 13% and the put/call ratio is 2.14.
↑ImprovingMomentum breakdown
- Expectation
- Price should reclaim the 200-day moving average and short interest should fall below 10%.
CounterDistribution volume with elevated short interest and put buying shows active bearish positioning.
Per-dimension breakdown
Quality
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.4 |
| ROA | 1.9 |
| Gross margin | 7.1 |
| Op margin | 4.1 |
| Net margin | 0.4 |
| Current ratio | 9.4 |
| FCF quality | 10.0 |
| Moat | 5.2 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 817% FCF/NI
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 8/9
Growth
3.1/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 3.1 |
Momentum
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.2 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+0.8%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.0 |
| Analyst rating | 5.0 |
| Price target | 7.2 |
Insider
5.4/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.8 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
2.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.8 |
| quality rank | 4.9 |
| growth rank | 1.3 |
Technical
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.1 |
| support resistance | 2.9 |
| 52w position | 3.2 |
Risk (lower is worse)
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.5 |
| days to cover | 4.1 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 5.9 |
| debt equity | 3.2 |
- ▸Elevated put/call: 5.25
- ▸High IV: 107%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 9.9 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Extreme risk factors.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:RISK_FLOORPassed (6)
- MOMENTUM:5.9>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:113d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.1<1.5@spot
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.07
Upside
+1.0%
Downside
14.2%
Sizing output
AVOID
SetupRange Bound — RSI 53 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($1.1B) below institutional reach
SuitabilityAggressive — MCap $1.1B<$5B
Investment implication
The SELL_IF_HOLDING verdict reflects the ASYMMETRY gate's 0.1<1.5@spot outcome against Value at 7.3 and asymmetric R:R of 0.07.
The strongest dimensions are Value at 7.3, Catalyst at 7.0, and Sentiment at 6.0; the weakest are Risk (lower is worse) at 2.4, Peer rank at 2.9, and Technical at 3.1. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.07 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Earnings Beat Streak
Trip ifEPS misses estimates in at least 2 of the next 4 quarters.
- P2Deeply Discounted Valuation
Trip ifForward P/E rises above 12x without an increase in earnings estimates.
- P3Upside To Analyst Target
Trip ifAnalyst target is cut below $12.00 from the current $14.11.
- P4Single Segment Concentration
Trip ifCSS segment revenue declines more than 10% YoY.
- P5Weak Momentum And Short Interest
Trip ifPrice falls below the $11.22 stop level from the current $11.91.